Phagenyx® for Healthcare Providers

Dysphagia is Common, Costly, and Harmful

Dysphagia is a frequent consequence of stroke and is associated with longer hospital stays, increased costs and aspiration-related complications. Conventional treatments may not target the disruption to the sensory nerves or brain areas that control swallowing, limiting the potential for functional recovery.

45%

of stroke patients suffer from persistent dysphagia1

10+ day longer

average length of stay2

8x higher mortality

at 3 months3

Severe dysphagia can cause:

  • Excessive secretion pooling
  • Significant pharyngeal residue
  • Impaired airway protection including silent aspiration

Which increases risk of:

  • Intubation
  • Inability to decannulate
  • PEG tube

Current Dysphagia Treatment Limitations

Current Treatments

Compensatory Interventions

  • No food by mouth (NPO) or modified diets
  • Alternate means of nutrition, including PEGs
  • Pneumonia prevention strategies

Rehabilitative Interventions

  • Swallowing exercises and maneuvers
  • Respiratory muscle strength training

Current Treatment Limitations

Targets Symptoms, Not Root Cause

No direct evidence of neuroplasticity

Limited Evidence-Base

Mixed evidence on current standard of care. Lack validated treatment protocols

Requires Active Patient Engagement

Makes early intervention more challenging

The Phagenyx System

Introducing the first and only clinically validated neuromodulation system using pharyngeal electrical stimulation (PES) to retrain the brain and restore swallowing control.

Faster Return to Oral Nutrition

6-day faster return to oral nutrition and 50% fewer patients dependent on feeding tubes at discharge4

Reduced Aspiration Risk

Greater than 2x improvement in swallowing safety5 

Shortened Length of Stay

8 fewer days in the hospital4 and 4x more patients ready for early decannulation6

Phagenyx Patient Selection

Patients with any of the following characteristics of severe dysphagia are candidates for Phagenyx treatment.

Abnormal laryngeal/pharyngeal sensation

or

Impaired swallow safety and efficiency

or

Reduced or absent spontaneous swallowing

Active patient engagement and participation is not required for Phagenyx treatment

What is Pharyngeal Electrical Stimulation (PES)?

A new approach to improving swallow safety & efficiency

Pharyngeal Electrical Stimulation (PES) is a neuromodulation therapy with demonstrated efficacy in neurogenic dysphagia. By activating pharyngeal afferent pathways, PES engages central swallowing networks, facilitating reorganization and promoting earlier, safer functional recovery.

  • Treats the neurological cause
    Addresses swallowing difficulty at its source by stimulating pharyngeal sensory nerves to reactivate brain pathways critical to swallowing.
  • Promotes neuroplastic recovery
    Triggers afferent signaling that facilitates cortical reorganization and supports the restoration of functional swallowing control.
  • Grounded in scientific rigor
    Foundational research and peer-reviewed publications prove brief pharyngeal stimulation induces lasting neuroplastic changes in cortical activity associated with swallowing control.
  • Validated with clinical evidence
    Randomized controlled trials demonstrate improvement in swallowing safety and efficiency, resulting in faster return to oral nutrition, reduced aspiration risk and shortened length of stay.

The Science of PES

Patient Story

Hear from Michael, a Certified Master Baker, about how Phagenyx therapy helped him regain the ability to swallow food after a massive stroke.

6 days

of PES led to return to normal swallowing

Cost Effectiveness of Phagenyx Treatment 

Phagenyx treatment for patients with severe dysphagia may result in annual cost savings.

0%

Fewer Reintubations

Fewer patients required reintubation after Phagenyx treatment, compared to control7

0%

Reduction in ICU Length of Stay

Patients treated with Phagenyx required 5.4 fewer days in the ICU, compared to control7

0

Fewer Days in the Hospital

Patients treated with Phagenyx were discharged from the hospital 8 days faster, compared to control7

Service & Support

With you every step of the way

Align stakeholders, confirm project timeline, assess site readiness and coordinate logistics to ensure a smooth and successful Phagenyx launch.

On-site comprehensive training for healthcare professionals, including guidance on patient selection, to support successful Phagenyx use.

Onsite and virtual support, tools and best practices, and outcome tracking to optimize Phagenyx success.

Supports long-term success through protocol integration, ongoing support, outcome reviews, and multiservice integration.

Bring Phagenyx to Your Hospital

Ready to transform your approach to post-stroke dysphagia recovery? Let’s start the conversation.

Contact Us

Questions?

Treatment Questions

Phagenyx may be appropriate for patients with reduced or absent spontaneous swallowing, impaired swallowing safety or efficiency, or abnormal sensation in the pharynx or larynx.

In the US, the Phagenyx is indicated for use in patients with severe dysphagia post stroke.

No, loop recorders and pacemakers have active electrical components and are contraindicated for Phagenyx treatment.

Availability Questions

In the US, Phagenyx is only available in acute care, inpatient settings. Please contact us at [email protected] for additional details.

To speak with a Phagenyx representative, contact us at [email protected].

Currently, Phagenyx treatment is only being offered in hospital in-patient settings.